Erytech shares crater as PhIIb AML study flops; Synlogic, Gingko collaborate on discovery work; Active Biotech forced to sell property due to Teva's drug failure
→ The French biotech Erytech Pharma $ERYP says that its Phase IIb trial of eryaspase for acute myeloid leukemia failed, triggering a rout of the biotech’s share price. The drug flunked the primary endpoint on overall survival in the trial, which recruited 123 patients over the age of 65. The stock plunged 28% on the news. “These data reflect the complexity of this disease, particularly in the older age group,” commented Iman El-Hariry, the CMO at Erytech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
